Raptiva (Genentech Inc)
Raptiva (Genentech Inc) Brand names, Raptiva (Genentech Inc) Analogs
Raptiva (Genentech Inc) Brand Names Mixture
- No information avaliable
Raptiva (Genentech Inc) Chemical_Formula
No information avaliable
Raptiva (Genentech Inc) RX_link
http://www.rxlist.com/cgi/generic3/raptiva.htm
Raptiva (Genentech Inc) fda sheet
Raptiva (Genentech Inc) msds (material safety sheet)
Raptiva (Genentech Inc) Synthesis Reference
sequence listed in Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol. 1996 Dec 1;157(11):4986-95
Raptiva (Genentech Inc) Molecular Weight
No information avaliable
Raptiva (Genentech Inc) Melting Point
61 oC (FAB fragment), 71 oC (whole mAb)-Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).
Raptiva (Genentech Inc) H2O Solubility
No information avaliable
Raptiva (Genentech Inc) State
Liquid
Raptiva (Genentech Inc) LogP
No information avaliable
Raptiva (Genentech Inc) Dosage Forms
Solution (Subcutaneous Injection)
Raptiva (Genentech Inc) Indication
For treatment of psoriasis
Raptiva (Genentech Inc) Pharmacology
Lymphocyte activation and trafficking to skin play a role in the pathophysiology of chronic plaque psoriasis. In psoriatic skin, ICAM-1 cell surface expression is upregulated on endothelium and keratinocytes. Raptiva inhibits the binding of LFA-1 to the intercellular adhesion molecule-1 (ICAM-1), thereby inhibiting the adhesion of leukocytes to other cell types.
Raptiva (Genentech Inc) Absorption
No information avaliable
Raptiva (Genentech Inc) side effects and Toxicity
No information avaliable
Raptiva (Genentech Inc) Patient Information
BIOD00074.html
Raptiva (Genentech Inc) Organisms Affected
Humans and other mammals
